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Cefuroxime axetil immediate release tablets were formulated by direct compression method with different 
percentages of sodium lauryl sulphate (SLS) such as 0.5, 1.0, 1.5 and also without SLS. Resulting 
batches of tablets were evaluated by both pharmacopeial and non-pharmacopeial methods to ascertain 
the physico-mechanical properties. Dissolution test were carried out in different medium like 0.07 M 
HCl, distilled water, 0.1M HCl of pH 1.2 and phosphate buffers at pH 4.5 and 6.8 to observe the drug 
release against the respective concentration of SLS used. Later, test formulations were compared by 
f1 (dissimilarity) and f2 (similarity) factors using a reference brand of cefuroxime axetil. Significant 
differences (p<0.05) in dissolution rate were recorded with the change in concentration of SLS in different 
media. Test formulation T3 containing 1% SLS was found to be best optimized formulation based on 
assay, disintegration, dissolution and similarity and dissimilarity factors.
Uniterms: Cefuroxime axetil/immediate release tablets/physico-mechanical properties. Direct 
compression. Sodium lauryl sulphate.
Formularam-se comprimidos de liberação imediata à base de cefuroxima axetil, pelo método de 
compressão direta, com diferentes percentagens de lauril sulfato de sódio (LSS), tais como 0,5, 1,0, 1,5, 
e também sem SLS. Os lotes resultantes dos comprimidos foram avaliados por ambos os métodos da 
farmacopeia e não farmacopeicos para determinar as propriedades físico-mecânicas. O teste de dissolução 
foi realizado em meios diferentes, como HCl 0,07 M, água destilada, HCl 0,1 M com pH 1,2 e os tampões 
fosfato (pH 4,5 e 6,8) para observar a liberação do fármaco contra a correspondente concentração de 
LSS utilizado. Em seguida, as formulações de teste foram comparadas por fatores f1 (dissimilaridade) 
e f2 (similaridade), utilizando uma marca de referência de cefuroxima axetil. Diferenças significativas 
(p<0,05) na taxa de dissolução foram registradas com a mudança na concentração de LSS em diferentes 
meios de dissolução. A formulação T3 contendo LSS a 1% foi considerada a melhor formulação otimizada 
com base nos ensaios de desintegração, dissolução e fatores de semelhança e dissimilaridade.
Unitermos: Cefuroxima axetil/comprimidos de liberação imediata/propriedades físico-mecânicas. 
Compressão direta. Lauril sulfato de sódio.
INTRODUCTION
The solubility of drugs plays a significant role in 
determining the rate and extent of its absorption, thus 
finally affecting its bioavailability. Therefore poorly 
soluble or water insoluble drugs need special consideration 
and strategies while designing their solid oral formulations. 
Rate of drug release from solid oral dosage forms is one of 
the leading factors, which helps to ascertain the therapeutic 
efficacy in view of the quantity of drug available for 
absorption and reaching into blood circulation. Although, 
the phenomenon is equally applicable and important for 
all active pharmaceutical ingredient(s) (API), however it 
is more challenging if the API is antibiotic due to specific 
action required against microbes.
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Most of the drugs launched in recent years have 
a poor aqueous solubility. Formulation of poorly water 
soluble drugs is really a challenge for today’s formulation 
scientists. Their absorption and bioavailability from 
gastrointestinal tract is greatly influenced by the crystalline 
state. Due to their variable bioavailability at a given dose, 
it might be difficult to predict their pharmacology and 
toxicology (Navnit et al., 2008).
Cefuroxime is a second generation cephalosporin 
antibiotic with a broad spectrum activity and a poor 
absorption profile from gastrointestinal tract. It led to 
the synthesis of the 1-acetoxyethyl ester of cefuroxime 
(cefuroxime axetil). Cefuroxime axetil is a prodrug 
of cefuroxime and is suitable for oral administration. 
Crystalline cefuroxime axetil still does not exhibit 
adequate bioavailability (<18%) when taken through 
oral route (Somani, Bhushan, Sen, 2001). It is important 
that cephalosporin compounds for oral administration 
should be in a form which provides high bioavailability 
(90-100%) so that their absorption into the blood stream 
is maximized and the amount of antibiotic remaining in 
the gastrointestinal tract is minimized.
According to the Biopharmaceutical Classification 
System (BCS), cefuroxime axetil is a poorly water soluble 
drug having class II qualities with low solubility but 
high permeability (Woo, Chang, 2000). Solubility and 
permeability are the important parameters in formulation 
development and regulatory standards. For BCS II, the 
rate limiting step or the slowest step is drug release from 
the dosage form and solubility in the gastrointestinal 
fluid and not the absorption; thus by increasing solubility, 
bioavailability also increases (Ketan, Anuradha, Jignasa, 
2012). Solubility of a drug can be enhanced by various 
means such as solvent deposition, solid dispersion, 
eutectic mixture, micronization, use of surfactant, 
molecular encapsulation etc. (Desai, Park, 2004).
The effects of surfactants on the dissolution of 
drugs have been individually investigated by many 
researchers for the past several decades. Surfactants act 
as an absorption enhancer and increase drug dissolution 
and permeability by promoting wetting and penetration of 
dissolution fluid into the drug molecules (De Smidt, Grit, 
Crommelin, 1994). Both ionic and cationic surfactants 
are effective but anionic surfactants such as sodium lauryl 
sulphate (SLS) have higher solubility than cationic ones. 
SLS has been proven as the agent of choice because it is 
inexpensive and possesses good solubilizing capacity at 
relatively low concentration. Various studies are available 
in the open literature that has highlighted the role of SLS as 
a solubility enhancer (De Smidt, Grit, Crommelin, 1994; 
Sun, Larive, Southard, 2003).
The aim of present work was to:
1. Formulate cefuroxime axetil immediate release tab-
lets by a direct compression method
2. Enhance solubility of cefuroxime axetil by using 
different concentrations of sodium lauryl sulphate
3. Evaluate blends and compressed tablets by both 
pharmacopeial and non-pharmacopeial methods
4. Study dissolution behavior of test formulations of 
cefuroxime axetil using different media
5. Compare test formulations with a reference brand by 
one way ANOVA and a model independent approach
MATERIAL AND METHODS
Cefuroxime axetil (CA) USP (Nectar Life Sciences, 
Ltd. India): 150mg of CA equivalent to 125 mg of 
cefuroxime. Other excipients used were: avicel PH 
102® (FMC, USA), starch 1500® (Pregelatinized starch) 
(Colorcon Ltd., England), sodium lauryl sulphate and 
magnesium stearate (Fischer, UK). Zinacef®(reference 
brand) 125 mg film coated tablet (GSK (Pvt) Ltd. Karachi, 
Pakistan) purchased from the local market. Software used 
were adds in program DD solver® and Microsoft Excel 
2010® for statistical analysis by one way ANOVA.
Manufacturing of cefuroxime axetil tablets
Formulation composition
Four formulations of cefuroxime axetil immediate 
release tables were designed for direct compression. 
Compositions were set in such a way that the active 
ingredient and excipients such as starch 1500 and 
magnesium stearate remain the same in all the formulations 
but the concentration of SLS was varied in each formulation 
and adjusted by avicel PH 102 (Table I). Total compression 
weight was set at an average weight of 450 mg (± 5%).
Blend preparation for compression
All the ingredients were accurately weighed, sieved 
manually through a 40 mesh sieve and then mixed in a 
polyethylene bag for 15 minutes. The mixture was then 
blended with magnesium stearate for another 5 minutes 
to get a homogenous blend.
Evaluation of flow properties
The flowability of the powder blends were evaluated 
under USP 36/ NF 31, 2013 guidelines as follows,
•	 Angle of repose (α)
Angle of repose (α) was determined by funnel 
method. Each blend was poured through a funnel that can 
be raised vertically until a maximum cone height (h) was 
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achieved. The radius of the heap (r) was measured and 
angle of repose calculated as, 
α = tan -1 ( h/r )
•	 Bulk density (ρb)
Apparent bulk density (ρb) was determined by 
introducing perceived blend of test formulations in to a 
graduated cylinder and measuring the weight (M) and bulk 
volume (V b) using the formula,
ρb = M/Vb 
•	 Tapped density(ρt)
Tapped density (ρt) was determined by tapping the 
known mass of a blend in a measuring cylinder for a fixed 
time. The minimum volume (Vt) occupied in the cylinder 
and weight (M) was measured and the tapped density 
calculated as,
ρt = M/ Vt 
•	 Compressibility Index
Powder compressibility is a more significant way 
to measure free flow properties is the ease by which a 
material can be persuade to flow and is calculated by % 
compressibility as follows: 
C = (ρt - ρb) / ρt *100
•	 Hausner’s ratio
Hausner’s ratio is an index of ease of powder flow 
and determined by following formula,
Hausner’s ratio = ρt/ρb
Tablet compression
Powder blends were compressed on a single punch 
machine (Korsch, Erweka, Germany) fitted with a convex 
shaped punch having a diameter of 12.38mm to get oval 
tablets each weighing 450mg (±5%). Hardness set for 
compression ranged between 6-7 kg. A minimum of fifty 
tablets were compressed for each batch on separate days 
at room temperature.
Tablets testing
The quality parameters of finished tablets were 
evaluated by USP 36/ NF 31, 2013 guidelines and non-
pharmacopeial methods as stated below.
Weight variation
The variation of the weight of individual tablets is 
an apparent indication of the corresponding variation in 
the drug content (Rawlins, 1995). The weight variation 
evaluation of test formulations and reference brand were 
carried out by individually weighing 20 tablets on a Type 
1 balance (Sartorious GmbH; type A 6801) and then mean 
weight and standard deviation were calculated.
Tablet thickness and diameter
The thickness of a tablet was the result of the amount 
of fill permitted to enter the die and the amount of pressure 
applied during compression (Allen, Popvich, Ancel, 2011). 
Diameter and thickness of 20 tablets, each of the innovator 
and test formulations, were determined by a vernier caliper 
in mm (CD-6, CSX, Mitutoyo, Japan).
Tablet hardness
To determine crushing strength, hardness of 
randomly selected 20 tablets of test formulations was 
determined in kg using a Hardness Tester (Fujiwara, 
Seisukusho Corporation, Japan).
Friability testing
Friability test was performed on 20 randomly 
selected tablets of each test formulations. Tablets were 
cleared from any loose dust by a soft brush and weighed 
accurately. Each set of tablets were placed separately in a 
friabilator (H.Jurgens and Co-GmbH, D2800, Germany) 
TABLE I - Composition of Cefuroxime Axetil formulations compressed by Direct compression method
Ingredients
T1 
Without SLS 
(mg/tab)
T2 
SLS 0.5% 
(mg/tab)
T3 
SLS 1% 
(mg/tab)
T4 
SLS 1.5% 
(mg/tab)
Cefuroxime axetil 150.00 150.00 150.00 150.00
Avicel PH 102 259.50 257.25 255.00 252.75
Sodium lauryl sulphate (SLS) 0 2.25 4.50 6.75
Starch 1500 31.50 31.50 31.50 31.50
Magnesium stearate 9.00 9.00 9.00 9.00
Total compression weight 450.00 450.00 450.00 450.00
T1= Test formulation one, T2= Test formulation two, T3= Test formulation three, T4= Test formulation four
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and run for 4 minutes (25 rpm). At the end of the test, 
tablets were removed, cleared from any loose dusts, 
observed for any capping and then their final weight was 
determined to calculate the loss of weight in percent.
Disintegration
The d is in tegra t ion  tes t  was  ensur ing  the 
dispensability of tablet content in purified water at a 
37 ± 0.5 °C temperature within appropriate time (Allen, 
Popvich, Ancel, 2011). Disintegration of compressed 
tablets and innovator was performed by placing each 
tablet in a tube of basket rack assembly of disintegration 
apparatus (Erweka, ZT2, Heusenstamm Germany).
Assay test method 
The test formulations and innovator were assayed by 
high performance liquid chromatography method (HPLC) 
as per USP 36/ NF 31, 2013 guidelines. The suitably 
filtered and degassed mixture of mobile phase composed 
of 0.2 M Monobasic ammonium phosphate and methanol 
(620:380) with a flow rate of 1.5 mL per minute. The liquid 
chromatography is equipped with a 278-nm detector (UV 
detector SPD 10-AVP, Shimadzu Corp., Tokyo, Japan), 
a pump LC-10 ADVP, Communication Bus Module 
CBM 102 and separation of drug was done by Promosil® 
(Agela Technologies, USA) C-18, 4.6 x 250-mm column 
containing 5μm packing with injection volume about 
10μL.
For assay preparation twenty tablets were accurately 
weighed and crushed in a porcelain mortar. Powder 
equivalent to 2 mg of Cefuroxime per mL transferred with 
the aid of methanol to a such capacity of volumetric flask 
and shaken by mechanical means for about 10 minutes. It 
was then diluted with methanol to a volume and filtered a 
portion of this stock mixture by Whatman® filter paper no. 
41. From this solution, 5 mL was promptly transferred to 
50 mL volumetric flask. This was followed by the addition 
of 5 mL of internal standard (Acetanilide in methanol 
containing 5.4 mg/mL), 8.8 mL of methanol and then diluted 
with 0.2M Monbasic ammonium phosphate to 50 mL. The 
solution was filtered through 0.45 μm Millipore® filter and 
injected in to the column, same procedure were carried out 
for reference standard solution of Cefuroxime axetil. The 
drug content was measured and calculated. The assay test 
method was carried out in triplicate.
In vitro dissolution studies
The dissolution studies of the compressed test 
tablets and reference brand were carried out as per USP 
36/ NF 31, 2013 guidelines by using a USP apparatus 
II (Erweka DT, Heusenstamm, Germany). Dissolution 
was performed in 900 ml of 0.07M HCl at 37 ± 0.5 oC 
at 100 rpm. An aliquot of 10 mL of solvent was taken 
out from vessels at 5, 10, 15, 20, 25, 30, 45, 60, 90 and 
120 minutes and volume was compensated by fresh 
medium. Drug concentration was calculated by UV-Vis 
spectrophotometer 1800 (Shimadzu, Kyoto, Japan) at 
278 nm with dissolution medium taken as blank. The 
dissolution profile was also established in distilled water, 
0.1 M HCl of pH 1.2 and phosphate buffers at pH 4.5, 
6.8 using the same sampling times as described above 
to evaluate the release of drug in the new formulations. 
Each experiment was repeated in triplicate.
RESULTS AND DISCUSSION
The solubility and dissolution factor of poorly soluble 
drugs in gastrointestinal fluid after oral administration is 
not only of great importance but also challenging at the 
same time. Therefore, such drugs require to be available 
in aqueous solution form at the absorption site. Further, 
due to the solubility factor, the poorly water soluble 
drugs usually need high dose in order to attain reasonable 
plasma peak concentration to achieve the desired 
therapeutic effect after oral administration. Apparently, 
this is not a good idea to proceed and formulate an oral 
dosage formulation of poorly soluble or insoluble drugs 
with this approach because this is very much likely 
to produce insufficient bio-availability, thus affecting 
therapeutic response. The partition coefficient of an active 
pharmaceutical ingredient(s) (API) does play a very 
important role in knowing its solubility or alternatively, 
the hydrophilicity or hydrophobicity of that API. In the 
present study as the drug chosen is cefuroxime axetil which 
is classified under class II of BCS (low solubility and 
high permeability), therefore considerable attention has 
been focused to design a suitable formulation which can 
increase its bioavailability and at the same time convenient 
in manufacturing, cost effective and reproducible.
Cefuroxime axetil (CA) is a prodrug which is 
hydrolyzed by esterase of the gut mucosa, releasing the 
active cefuroxime base. It has in-vitro microbial activity 
similar as the parent cefuroxime. The bioavailability 
and pharmacokinetics of the drug has been observed to 
vary depending on the physical form and having more 
stability in dosage forms (Perry, Brogden, 1996). Several 
reports confirm that the bioavailability can be improved 
by using different solubilizers and hence improving the 
solubility and permeability issues of the drug (Somani, 
Sethi, Tyagi, 2003). In the present study, cefuroxime axetil 
immediate release tablets were formulated with different 
concentrations of sodium lauryl sulphate (Table I). 
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The direct compression (DC) method was selected for 
manufacturing. Direct compression method is more 
convenient, economical and increases the stability 
of active ingredients by reducing detrimental effects 
(Shangraw et al., 1988). This method was also successfully 
used by Nanjwade et al. in making immediate release 
cefuroxime axetil tablets (Nanjwade et al., 2010).
Micromeritic evaluation of all formulation blends 
(T1-T4) revealed that angle of repose, bulk density, tapped 
density, Hausner’s ratio and compressibility index, was 
within the limits as specified by USP 36/ NF 31, 2013. 
Test three (T3) blend showed excellent flow while test 
one (T1), test two (T2) and test four (T4) showed a good 
flow (Table II). Good flow of the blends might be due to 
appropriate composition of avicel PH 102 and magnesium 
stearate in all formulations (Lahdenpaa, Niskanen, 
Yliruusi, 1997).
After ascertaining flowability, blends were 
compressed on single punch machine and the compressed 
tablets were evaluated for pharmaceutical attributes. 
Tablets were easily compressed and found to be free from 
any compression defects such as breaking, sticking and 
lamination. Weight variation was easily monitored within 
the prescribed limits as specified by USP 36/ NF 31, 
2013 guidelines while the thickness ranged within ± 5%. 
The hardness of all formulations was found to be 6.23 to 
7.02 kg. T1, T3 and T4 showed almost same hardness (6.83, 
6.23 and 6.42 kg respectively) while T2 showed highest 
hardness (7.02 kg). For a satisfactory tablet, hardness of 
5 kg is usually consider suitable and is use as a guide in 
compression. When the tablets were subjected to friability 
testing, results were found to be within the acceptable limits 
(0.31 to 0.57%). It directly relates to the tablet hardness and 
strength which is in proportion to the composition of the 
formulation (Table III). Zhang et al., in 2003, reported the 
physical properties of commonly used direct compression 
binder and explained the effect of avicel PH 102 and starch 
on tablet dosage forms (Zhang, Law, Chakrabarti, 2003).
The conventional immediate release oral solid 
dosage forms need to be disintegrated from its intact 
TABLE II - Flow properties of Cefuroxime axetil 125 mg directly compressible blends
Test 
Formulation
Mass
(g)
Bulk 
Volume
(mL)
Tapped 
Volume
(mL)
Bulk 
Density
(g/mL)
Tapped 
Density
(g/mL)
Angle of 
Repose
(θ-1)
Compressibility 
Index
(%)
Hausner 
Ratio
-
T1 8.05±0.05 9.85±0.06 8.65±0.07 0.81±0.03 0.93±0.12 33.20±0.06 12.90±0.05 1.14±0.01
T2 9.38±0.09 10.35±0.10 9.10±0.15 0.90±0.01 1.03±0.05 31.26±0.05 12.62±0.04 1.14±0.02
T3 8.50±0.15 10.10±0.12 9.15±0.05 0.84±0.02 0.92±0.11 28.88±0.04 8.69±0.03 1.09±0.01
T4 9.54±0.03 10.40±0.05 9.15±0.01 0.91±0.01 1.04±0.06 33.69±0.06 12.50±0.05 1.14±0.02
T1= Test formulation one, T2= Test formulation two, T3= Test formulation three, T4= Test formulation four. Each value is a 
Mean±SD of three determination
TABLE III - Pharmaceutical characteristics of reference and compressed formulations of Cefuroxime axetil
Test Formulation
Wt.Variation 
(Mean ±S.D)
(mg)
Thickness 
(Mean ±S.D)
(mm)
Diameter 
(Mean ±S.D)
(mm)
Hardness 
(Mean ±S.D)
(kg)
Friability 
(Mean ±S.D)
(%)
Disintegration
Time 
(Mean ±S.D)
(Seconds)
Assay HPLC 
(Mean ±S.D)
(%)
Pharmacopoeial 
Limits (USP 32/
NF 27)
±5% ±5% - At least 5 kg NMT 1% NMT 15 min. 90-110%
A1 Ref. 227.10±1.16 3.43±0.04 12.04±0.20 NA NA 47.33±0.58 98.84±0.29
T1 450.00±4.23 4.10±0.05 12.38±0.04 6.83±0.91 0.57±0.12 61.33±3.06 93.58±0.73
T2 450.45±3.70 4.11±0.05 12.38±0.05 7.02±0.95 0.37±0.10 59.00±1.00 94.94±0.99
T3 450.31±3.51 4.08±0.03 12.37±0.04 6.23±0.38 0.31±0.14 51.33±0.58 101.43±0.79
T4 449.86±3.71 4.10±0.04 12.38±0.04 6.42±0.63 0.41±0.13 54.00±1.00 101.85±0.41
A1 Ref = Ref. coated brand of GSK, Pakistan., T1= Test formulation one, T2= Test formulation two, T3= Test formulation three, 
T4= Test formulation four, NA= not applicable
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form and get dissolved to show its release pattern. Thus 
the inclusion of the right disintegrant is a prerequisite for 
optimal bioavailability (Bhowmik et al., 2010). In the 
present study, all the test formulations were disintegrated 
quickly within one minute and were in compliance with 
USP guidelines. Starch 1500 (pregelatinized starch) is 
widely used as a disintegrant in tablet manufacturing 
and in one study, formulation of lamivudine tablets with 
starch 1500 exceeded the disintegration and dissolution 
performance (Rahman et al., 2008).
Pharmaceutical assay was performed by high 
performance liquid chromatography method (HPLC). 
Assay results for test and reference formulations 
were within USP 36/ NF 31, 2013 limits (90-110%). 
This indicates that the blending time selected for test 
formulations was appropriate and resulted in a uniform 
random blend (Table III and Figure 1, 2). 
The multiple point dissolution studies of cefuroxime 
axetil tablets were performed in five different dissolution 
medium i.e., 0.07 M HCl (USP dissolution medium), 
FIGURE 1 - HPLC Chromatogram of standard solution containing internal standard, acetanilide (6.18 min), cefuroxime axetil 
diastereoisomer B (11.23 min) and cefuroxime axetil diastereoisomer A (12.83 min).
FIGURE 2 - HPLC Chromatogram of test formulation T3 solution containing internal standard, acetanilide (4.80 min), cefuroxime 
axetil diastereoisomer B (9.88 min) and cefuroxime axetil diastereoisomer A (11.49 min).
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0.1 M HCl of pH 1.2, phosphate buffers (pH 4.5 and 6.8) 
and distilled water. In test formulation one (T1), which was 
formulated without SLS, less drug released was observed 
in 0.07 M, 0.1 M HCl, and phosphate buffers pH 4.5 and 
6.8 (range: 60.34±0.87 - 70.35±1.35) but more than 80% 
(81.33±1.14) drug was released in water in one hour. In 
case of test formulation two (T2) which was formulated 
with 0.5% of SLS, lowest drug release was found in 
0.1 M HCl (36.59±0.86) while almost same drug release 
were detected in other tested medium in one hour sampling 
time (range: 72.31±1.08-82.52±1.56). Dissolution results 
of test formulation three (T3) was very promising which 
was formulated with 1% SLS. Highest drug release was 
FIGURE 3 - Released pattern of Reference and test formulations in 0.07 M HCl dissolution medium (Mean±SD).
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FIGURE 4 - Released pattern of Reference and test formulations in distilled water dissolution medium (Mean±SD).
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found in phosphate buffer pH 4.5 (91.81±0.60) while all 
the other tested medium showed more than 80% (range: 
82.34±0.61-84.12±1.10) drug release within one hour. 
Likewise T1 and T2, test formulation four (T4) which 
was formulated with 1.5% SLS also showed somewhat 
lower release rates in 0.07 M HCl (63.46±1.19) but 
more promising release rate in 0.1 M HCl (77.59±1.85) 
within one hour of dissolution testing. In other medium, 
T4 showed highest release pattern in pH 6.8 phosphate 
buffer followed by 4.5 phosphate buffer and distilled water 
(Figure 3, 4, 5, 6 and 7).
When results were subjected to statistical analysis 
by one way ANOVA, revealed a significant difference 
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FIGURE 5 - Released pattern of Reference and test formulations in pH 1.2 (0.1 M HCl) dissolution medium (Mean±SD).
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FIGURE 6 - Released pattern of Reference and test formulations in pH 4.5 (Phosphate Buffer) dissolution medium (Mean±SD).
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(p<0.05) among reference and test formulation (T1-T4) 
in all dissolution medium at each sampling time, except in 
test formulation three (T3) in 0.1 M HCl a non-significant 
difference (p>0.05) were observed at 45 minutes time 
interval. This result indicates the role of sodium lauryl 
sulphate as a solubility enhancing agent for poorly water 
soluble drugs. It also revealed that 1% SLS is appropriate 
for enhancing solubility of cefuroxime axetil tablets, which 
is in line with Muhammad et al. (2012) studies conducted 
recently in the same dissolution medium. It appears that 
in the present study, SLS due to its anionic nature favors 
maximum micelle formation at 1% concentration and 
thus increases the dissolution rate of cefuroxime axetil. 
Use of SLS from 0.5-2% was also recommended by the 
FDA for poorly soluble drugs (Chilukuri, Sunkara, Young, 
2007). Razzka et al. (2012), studied the effect of different 
concentrations of SLS on the release of carbamazepine 
matrix tablets and reported promising results. In another 
study Jinno et al. (2000) also reported effect of surfactants 
on the dissolution profile of poorly water soluble weakly 
acidic drugs and reported SLS as the best choice for 
micelle formation and solubility enhancement.
A model independent approach as recommended by 
Moore and Flenner (1996) that comprises of calculating 
a dissimilarity factor (f1) and a similarity (f2) factor 
were also done to compare an innovator brand with the 
test formulations. It is reported in the previous works 
that the dissolution and pH solubility outcomes of both 
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drugs and prodrugs could be relevant and the FDA and 
ICH recommends f1 and f2 factors for the comparison 
of dissolution profiles (FDA, 1997; 2003). Dissolution 
curves considered to be equivalent if f1 ranges from 1-15 
and f2 ranges from 50-100. Test formulation three (T3) 
showed a smallest differential values for f1 (10.43, 7.04, 
6.02, 8.40, 8.83) and a good similarity values for f2 (50.54, 
58.10, 60.18, 52.60, 54.04) in dissolution media (Table 
IV). Previously for cefuroxime axetil, similar finding have 
been reported by Iyad et al. who used model independent 
approach using f2 factor only (Muhammad et al., 2012).
CONCLUSION
Cefuroxime axetil 125 mg tablets were successfully 
formulated by direct compression method. Likewise 
previous studies, incorporation of sodium lauryl sulphate 
in the present study was found to be beneficial in 
enhancing solubility of poorly soluble drugs. Dissolution 
rate of Cefuroxime axetil was studied in various medium 
including USP dissolution medium that gave a chance to 
compare its release rate in various media and to select the 
best medium for this drug. Use of f1 and f2 further give 
an insight about the in-vitro performance of Cefuroxime 
axetil. Further studies using other surfactants or other 
approaches for enhancing solubility are recommended 
for future workers.
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TABLE IV - Difference factor (f1) and similarity factor (f2) of all formulation with Reference at different pH
S. No Formulations comparison Factor
0.07 M HCl 
(D.M)
Distilled 
water
pH 1.2 (0.01M 
HCl)
pH 4.5 
Phosphate 
buffer
pH 6.8 
Phosphate 
buffer
1. A1 Ref. vsT1
f1 51.12 23.53 49.61 36.74 33.67
f2 15.96 32.09 16.94 20.91 25.59
2. A1 Ref. vsT2
f1 28.69 30.63 60.02 15.86 22.14
f2 28.81 26.11 13.64 40.85 32.19
3. A1 Ref. vsT3
f1 10.43 7.04 6.02 8.40 8.83
f2 50.54 58.10 60.18 52.60 54.04
4. A1 Ref. vsT4
f1 52.09 34.35 32.95 29.26 16.24
f2 15.82 24.38 20.86 25.76 36.65
FIGURE 7 - Released pattern of Reference and test formulations in pH 6.8 (Phosphate buffer) dissolution medium (Mean±SD).
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publication at Second National Conference on Pharmacy 
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